Aer Therapeutics

Focus: Aer Therapeutics is a North Carolina-based biotech focused on developing therapeutic solutions for muco-obstructive lung diseases, particularly COPD. The company operates as a pre-revenue biotech with an early-stage pipeline.

Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Aer Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Aer Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AER-01

COPD

Phase 1

Clinical Trials (1)

NCT05862623Single and Multiple Ascending Dose Study of AER-01

Phase 1

Help build intelligence for Aer Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused niche in respiratory disease with high unmet medical need in COPD management
Early-stage opportunity to shape drug development strategy and clinical programs from the ground up
Specialized therapeutic area allows deep expertise building in muco-obstructive lung disease mechanisms

Watch Out For

Zero active job openings indicates company may not be hiring or is in a lean operational phase
Pre-revenue stage with unknown funding and financial runway creates employment stability uncertainty
Early pipeline (Phase 1–2 only) with no near-term catalysts or commercial inflection points visible

Generated by Claude from Aer Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

fexlamose

COPD

Phase 2

Clinical Trials (1)

NCT06731959A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Respiratory

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Respiratory

2 pipeline

Marketed

Pipeline